Femasys Inc Stock News

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company's strategic approach to capital deployment and strengthening its already solid financial position. Following the monetization of the stake, PharmaCyte's cash and marketable secu...

-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured convertible notes for total potential proceeds of $58 million, if all warrants are exercised for cash, reflecting strong investor confidence in Femasys' women's health mission --

SAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, is pleased to announce that it will exhibit at the American Society for Reproductive Medicine (ASRM) 2025 Scientific Congress & Expo, which will take place October 25-29 ...

-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth -- -- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth --

Expands international footprint with entry into Asia-Pacific, building on recent CE Mark and UK approvals Expands international footprint with entry into Asia-Pacific, building on recent CE Mark and UK approvals

ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 10,434,586 shares of its common stock,...

Femasys Revenue Jumps 85 Percent in Q2

-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the second quarter of 2025.